Inductive Bio
The Enterprise Lead will work directly with large pharma leaders and scientists to uncover opportunities, develop and test new offerings, and shape commercial strategies for scaling Inductive Bio's AI-driven drug discovery platform. This role involves translating customer insights into product capabilities, building relationships, and creating repeatable playbooks for selling and delivering solutions within complex pharmaceutical organizations.
Company Size
1-10 employees
Inductive Bio is an AI-powered virtual lab for drug discovery, helping pharmaceutical and biotech teams evaluate and optimize small molecule candidates faster. Their platform includes Beacon-1 ADMET models (ranked first in multiple global blind ADMET benchmarks), Compass software for running virtual experiments, and Indy, an AI chemistry assistant that automates time-consuming operations. Backed by a pre-competitive industry data consortium and embedded expert services, Inductive Bio enables end-to-end AI-informed design-make-test cycles to accelerate development candidates.
Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
May 7, 2025
Inductive Bio gains $21m ARPA-H funds for drug prediction models
Dec 9, 2025
Fixing drug discovery’s most persistent problem with AI
Jul 10, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Inductive Bio.
36% above the average for this role
Novel AI Drug Toxicity Models to Improve Drug Safety to Be Developed by an Industrial-Academic Group
Dec 10, 2025